A system of individual immunotherapy with leakadin in the combined therapy of acoustic neurinomas
Starchenko, A.A.; Khil'ko, V.A.; Komarets, S.A.; Khlunovskiĭ, A.N.; Prilukova, T.I.; Kraskovskaia, S.V.; Danilov, A.V.
Zhurnal Voprosy Neirokhirurgii Imeni N. N. Burdenko 4: 15-18
1996
ISSN/ISBN: 0042-8817 PMID: 9092246 Document Number: 455989
Analyzing the immunological responsiveness of patients with acoustic neurinomas on the antitumor immunomodulator leacadin has revealed some significant features. In leacadin-treated patients, postimmunotherapy promotes the formation of high sanogenetic responses: an increase in the rigidity of the brain-immune system; elevations of the levels of antitumor factors of the immune system: T helper cells and locally synthesized antibodies; a decrease in neuro-sensitization after tumor removal, which prevents tumor stimulation and recurrence; an indirect reduction in the activity of T suppressors that inhibit immunological responses in growing neoplasm. Immunotherapy with the antitumor immunomodulator leacadin in patients with acoustic neurinomas contributes to the development and optimization of the tumor carrier's immunological adaptative responses, creates conditions for the optimal postoperative course and prevents recurrence.